Radiofrequency Ablation and Chemotherapy vs Chemotherapy Only in Locally Advanced Pancreatic Cancer: The PELICAN Randomized Clinical Trial - PubMed
6 hours ago
- #pancreatic cancer
- #radiofrequency ablation
- #chemotherapy
- This randomized clinical trial (PELICAN) investigated if adding radiofrequency ablation (RFA) to chemotherapy improves survival in patients with nonprogressive, locally advanced pancreatic cancer.
- The study included 188 patients randomized to either RFA plus chemotherapy or chemotherapy alone after 2 months of induction chemotherapy.
- After a median follow-up of 55 months, overall survival was similar between groups: 12.1 months for RFA plus chemotherapy vs 11.6 months for chemotherapy alone.
- Progression-free survival and serious adverse events (grade 3 or higher) were worse in the RFA group, with 27% experiencing serious events vs 11% in the chemotherapy-only group.
- Quality of life declined more significantly in the RFA group, exceeding clinically relevant thresholds at multiple time points.
- The trial concluded that adding RFA to chemotherapy did not improve survival and negatively impacted patient quality of life.